Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Corcept Therapeutics Incorporated CORT
$23.76
-$0.15 (-0.63%)
На 18:00, 12 мая 2023
+26.26%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2423143190.00000000
-
week52high
30.14
-
week52low
17.29
-
Revenue
401858000
-
P/E TTM
28
-
Beta
0.50138400
-
EPS
0.86000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 10:59
Описание компании
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 04 авг 2022 г. |
| Truist Securities | Hold | Buy | 01 авг 2022 г. |
| Canaccord Genuity | Buy | 02 февр 2022 г. | |
| Truist Securities | Buy | 28 янв 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 23 июн 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 09 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Maduck Sean | D | 31977 | 625 | 01 дек 2022 г. |
| Maduck Sean | D | 56462 | 625 | 01 дек 2022 г. |
| Maduck Sean | A | 57087 | 625 | 01 дек 2022 г. |
| Robb Gary Charles | D | 21143 | 186 | 23 ноя 2022 г. |
| Robb Gary Charles | D | 21329 | 4814 | 22 ноя 2022 г. |
| Robb Gary Charles | D | 26143 | 13401 | 18 ноя 2022 г. |
| Robb Gary Charles | D | 39544 | 10000 | 17 ноя 2022 г. |
| Maduck Sean | D | 32602 | 25000 | 10 ноя 2022 г. |
| Maduck Sean | D | 56462 | 25000 | 10 ноя 2022 г. |
| Maduck Sean | A | 81462 | 25000 | 10 ноя 2022 г. |
Новостная лента
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
Zacks Investment Research
04 мая 2023 г. в 16:43
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
Corcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Call Transcript
Seeking Alpha
03 мая 2023 г. в 23:43
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Bill Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann David Amsellem - Piper Sandler Edward Nash - Canaccord Genuity Greg Fraser - Truist Operator Good day and thank you for standing by. Welcome to the Corcept Therapeutics conference call.
Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates
Zacks Investment Research
03 мая 2023 г. в 19:02
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.20 per share a year ago.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
Zacks Investment Research
02 мая 2023 г. в 14:32
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
GlobeNewsWire
26 апр 2023 г. в 16:05
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).